Analytical Validation of the PreciseDx Digital Prognostic Breast Cancer Test in Early-Stage Breast Cancer.

Gerardo Fernandez¹, Jack Zeineh², Marcel Prastawa², Richard Scott², Abishek Sainath Madduri¹, Alexander Shtabsky², Shabnam Jaffer³, Aaron Feliz², Brandon Veremis¹, Juan Carlos Mejias², Elizabeth Charytonowicz¹, Nataliya Gladoun¹, Giovanni Koll², Kristian Cruz², Doug Malinowski², Michael J Donovan⁴

¹PreciseDx, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY.

²PreciseDx, New York, NY.

³Lenox Hill Hospital, New York, NY.

⁴PreciseDx, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY; University of Miami, Pathology, Miami, FL. Electronic address: mdonovan@precisedx.ai.

PubMed DOI

Abstract

BACKGROUND: PreciseDx Breast (PDxBr) is a digital test that predicts early-stage breast cancer recurrence within 6-years of diagnosis. MATERIALS AND METHODS: Using hematoxylin and eosin-stained whole slide images of invasive breast cancer (IBC) and artificial intelligence-enabled morphology feature array, microanatomic features are generated. Morphometric attributes in combination with patient's…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.